Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) saw a significant decrease in short interest in December. As of December 15th, there was short interest totaling 407,422 shares, a decrease of 31.2% from the November 30th total of 592,267 shares. Based on an average trading volume of 240,762 shares, the short-interest ratio is presently 1.7 days. Approximately 1.6% of the company’s shares are short sold. Approximately 1.6% of the company’s shares are short sold. Based on an average trading volume of 240,762 shares, the short-interest ratio is presently 1.7 days.

Hedge Funds Weigh In On Adial Pharmaceuticals

A hedge fund recently bought a new stake in Adial Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 143,791 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned about 0.60% of Adial Pharmaceuticals at the end of the most recent reporting period. 16.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ADIL has been the subject of a number of research reports. Maxim Group raised shares of Adial Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research report on Tuesday, September 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $1.50.

Adial Pharmaceuticals Trading Down 0.5%

ADIL opened at $0.23 on Tuesday. Adial Pharmaceuticals has a twelve month low of $0.22 and a twelve month high of $1.30. The firm has a market cap of $6.17 million, a price-to-earnings ratio of -0.31 and a beta of 1.11. The company has a fifty day simple moving average of $0.31 and a 200 day simple moving average of $0.35.

Adial Pharmaceuticals (NASDAQ:ADIL) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. On average, analysts forecast that Adial Pharmaceuticals will post -1.53 earnings per share for the current fiscal year.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.